



**UNIVERSITI PUTRA MALAYSIA**

***PRODUCTION OF NOVEL ANTIMICROBIAL PEPTIDE HUMAN BETA  
DEFENSIN 9 AND ITS EFFICACY AGAINST COMMON EYE  
PATHOGENIC  
BACTERIA IN DIFFERENT SALT CONCENTRATION***

**NURUL ATIKAH BINTI AB HAMID**

**FPSK(M) 2018 25**



**PRODUCTION OF NOVEL ANTIMICROBIAL PEPTIDE HUMAN BETA  
DEFENSIN 9 AND ITS EFFICACY AGAINST COMMON EYE PATHOGENIC  
BACTERIA IN DIFFERENT SALT CONCENTRATION**

By

**NURUL ATIKAH BINTI AB HAMID**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in  
Fulfillment of the Requirements for the Degree of Master of Science**

**April 2018**

## **COPYRIGHT**

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**PRODUCTION OF NOVEL ANTIMICROBIAL PEPTIDE HUMAN BETA DEFENSIN 9 AND ITS EFFICACY AGAINST COMMON EYE PATHOGENIC BACTERIA IN DIFFERENT SALT CONCENTRATION**

By

**NURUL ATIKAH BINTI AB HAMID**

**April 2018**

**Chairman : Ho Kok Lian, PhD**  
**Faculty : Medicine and Health Sciences**

Beta defensins are small cationic peptide secreted by the surface epithelium in response to microbial threat. The human beta-defensin 9 (hBD9) is a relatively new defensin and its role as antimicrobial agent has not been described previously. In this study, *Escherichia coli Mach 1* and *E.coli BL21 (DE3)* were used as cloning and protein expression hosts respectively. HBD9 gene was fused to a protein expression vector using the small ubiquitin-related modifier (SUMO) fusion system. The soluble hBD9-SUMO fusion protein expressed was purified by Ni-IDA immobilised metal affinity chromatography (IMAC) and SUMO was removed by SUMO protease. This study defined the novel antimicrobial peptide hBD9 and its efficacy against common Gram-positive and negative bacteria. *Staphylococcus aureus* and *Pseudomonas aeruginosa* were chosen because they are common bacteria that causing eye infection. The Minimal inhibitory concentration (MIC) and Minimal bactericidal concentration (MBC) of the hBD9 were determined for these microbes. Interestingly, hBD9 showed antimicrobial activity against *Staphylococcus aureus* but not *Pseudomonas aeruginosa*. Salt sensitivity and cationic concentration were tested by incubation with NaCl and MgCl<sub>2</sub> using liquid culture containing hBD9 to analyse the effects of NaCl and MgCl<sub>2</sub> concentration on the antimicrobial activity. Antimicrobial activity against *Staphylococcus aureus* of hBD9 was not suppressed by NaCl and MgCl<sub>2</sub>. All the antimicrobial property of the hBD9 protein against the common bacteria was verified by using conventional methods. The results improved the current knowledge on the hBD9 and its antimicrobial properties. This will drive towards the discovery of a broad spectrum, safe by effective resistant-free antibiotic in the future. The finding of this study can be used as a reference in the future investigation and it might benefits scientific community to better by others scientist or researchers to increase understanding and find new effective antibiotics.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**PENGHASILAN ANTIMIKROBIAL PEPTIDE BETA DEFENSIN 9  
MANUSIA DAN KEBERKESANANNYA TERHADAP PATOGENIK  
BAKTERIA MATA DALAM PELBAGAI KEPEKATAN GARAM**

Oleh

**NURUL ATIKAH BINTI AB HAMID**

April 2018

**Pengerusi : Ho Kok Lian, PhD**  
**Fakulti : Perubatan dan Sains Kesihatan**

Defensin beta adalah peptida kationik kecil yang dirembeskan oleh epitelium permukaan sebagai tindak balas terhadap ancaman mikrob. Defensin beta manusia 9 (hBD9) adalah defensin yang agak baru dan peranannya sebagai agen antimikrobial tidak digambarkan sebelum ini. Dalam kajian ini, *E.coli* Mach 1 digunakan untuk pengklonan klon dan *E.coli* BL21 (DE3) digunakan sebagai tuan rumah ekspresi. Sistem penggabungan yang berkaitan ubiquitin kecil (SUMO) digunakan. Protein gabungan yang disahkan telah disucikan oleh IMAC Ni-IDA dan dipotong oleh protease SUMO. Kajian ini menerangkan novel antimikrobial peptide hBD9 dan keberkesanannya terhadap bakteria biasa Gram positif dan negatif. *Staphylococcus aureus* dan *Pseudomonas aeruginosa* dipilih kerana bakteria biasa yang menyebabkan jangkitan mata. Kepekatan menghalang Minimal (MIC) dan kepekatan bakterisidal Minimal (MBC) hBD9 telah menentukan untuk organisma. Yang penting, hBD9 menunjukkan aktiviti antimikrobial terhadap *Staphylococcus aureus* tetapi bukan *Pseudomonas aeruginosa*. Kepekaan garam diuji dengan inkubasi dengan NaCl dan konsentrasi kationik diuji dengan inkubasi dengan MgCl<sub>2</sub> ke dalam kultur cair yang terkandung hBD9 untuk menganalisis kesan kepekatan NaCl dan MgCl<sub>2</sub> terhadap aktiviti antimikroba. Aktiviti antimikrobik terhadap *Staphylococcus aureus* hBD9 tidak ditekan oleh NaCl dan MgCl<sub>2</sub>. Semua sifat antimikrobial protein hBD9 terhadap bakteria biasa disahkan dengan menggunakan kaedah konvensional. Hasilnya meningkatkan pengetahuan semasa mengenai hBD9 dan sifat antimikrobanya. Ini akan mendorong kepada penemuan spektrum yang luas, selamat oleh antibiotik bebas tahanan yang berkesan pada masa akan datang. Maklumat baru ini boleh digunakan sebagai rujukan dalam penyiasatan masa depan. Analisis ini mungkin bermanfaat oleh saintis atau penyelidik yang lain untuk meningkatkan kefahaman dan mencari antibiotik yang berkesan baru.

## ACKNOWLEDGEMENT

*In the name of Allah, the Most Gracious, the Most Merciful  
All gratification are referred to Allah*

All praise is to Allah, the Almighty for His consent for giving me the courage and strength in completing my Master study and research.

Firstly, I would like to take this opportunity to acknowledge and thank to those who have made this work possible. I would like to express my sincere thanks and gratitude to my late supervisor Almarhum Assoc. Prof. Dr. Nazri bin Omar for his strong support and guidance along my Master journey. I would like to thank the rest of my supervisors; Dr. Ho Kok Lian and Assoc. Prof. Dr. Rukman bin Awang Hamat. Without them, this dissertation would not have been possible. I thank to them for their patience, encouragement, inspiration, valuable guidance and professional advices throughout the tenure of my study.

A sincere gratitude and appreciation also go to Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, the place that has granted me the opportunity and amenities to collect the essential practical skills and the keen in fulfilling the research. Special note of thanks goes to all medical laboratory technologists, staffs and friends of Chemical Pathology's Laboratory and Surgery's department especially Ophthalmology Unit at this faculty for their constructive assistance while struggling the handiness laboratory tasks.

Last but not least, heartfelt gratefulness is extended to my family and friends for their tireless love, support, encourage and motivation throughout my study. Thank you and may peace and blessing be upon those who read.

I certify that a Thesis Examination Committee has met on 16 April 2018 to conduct the final examination of Nurul Atikah binti Ab Hamid on her thesis entitled "Production of Novel Antimicrobial Peptide Human Beta Defensin 9 and its Efficacy Against Common Eye Pathogenic Bacteria in Different Salt Concentrations" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Master of Science.

Members of the Thesis Examination Committee were as follows: -

**Yong Yoke Keong, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Leslie Than Thian Lung, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Internal Examiner)

**Alfizah binti Hanafiah, PhD**

Senior Lecturer  
Universiti Kebangsaan Malaysia  
Malaysia  
(External Examiner)



---

**RUSLI HAJI ABDULLAH, PhD**  
Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 30 July 2018

This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Ho Kok Lian, PhD**

Senior Lecturer  
Faculty Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Rukman Awang Hamat, PhD, MBBS, MPath**

Associate Professor  
Faculty Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

---

**ROBIAH BINTI YUNUS, PhD**  
Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:



## Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Name and Matric No.: Nurul Atikah binti Ab Hamid, GS45587

## Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: \_\_\_\_\_

Name of Chairman  
of Supervisory  
Committee:

Dr. Ho Kok Lian

Signature: \_\_\_\_\_

Name of Member  
of Supervisory  
Committee:

Associate Professor Dr. Rukman Awang Hamat

## TABLE OF CONTENTS

		Page
<b>ABSTRACT</b>		i
<b>ABSTRAK</b>		ii
<b>ACKNOWLEDGEMENT</b>		iii
<b>APPROVAL</b>		iv
<b>DECLARATION</b>		vi
<b>LIST OF FIGURES</b>		x
<b>LIST OF ABBREVIATIONS</b>		xiii
 <b>CHAPTER</b>		
<b>1</b>	<b>INTRODUCTION</b>	1
1.1	Background	1
1.2	Objectives	3
1.2.1	General objectives	3
1.2.2	The specific objectives of this study includes:	3
<b>2</b>	<b>LITERATURE REVIEW</b>	4
2.1	Antimicrobial Peptides (AMPs)	4
2.2	Defensin	6
2.2.1	Structure and function of defensin	6
2.2.2	$\alpha$ -defensin	7
2.2.3	$\beta$ -defensin	8
2.3	Small ubiquitin-related modifier (SUMO)	9
2.3.1	SUMO proteases	10
2.4	The anatomy of human of eyes	10
2.4.1	Roles of AMPs at Ocular surface	11
2.4.2	Bacteria Infection of the Eyes	12
2.5	Antimicrobial activities	12
<b>3</b>	<b>METHODOLOGY</b>	14
3.1	Study Design	14
3.2	List of chemicals, reagents and apparatus	15
3.2.1	Chemicals and reagents for cloning of DEFB109 gene	15
3.2.2	Apparatus for cloning of <i>DEFB 109</i> gene	15
3.2.3	Chemical and reagent for expression of hBD9	15
3.2.4	Apparatus for expression of hBD9	15
3.2.5	Chemical and reagent for purification of hBD9 protein	16
3.2.6	Apparatus for purification of hBD9 protein	16
3.2.7	Chemical and reagent for antimicrobial assay and salt sensitivity	16
3.2.8	Apparatus for antimicrobial assay and salt sensitivity	16
3.3	Methodology	17
3.3.1	Cloning	17
3.3.1.1	Plasmid extraction	17

	3.3.1.2	Polymerase chain reaction (PCR)	17
	3.3.1.3	Preparation of competent cell (Mach 1)	18
	3.3.1.4	Transformation of SUMO-DEFB 109 plasmid	18
	3.3.1.5	Colony selection and plasmid DNA isolation	18
	3.3.2	Fusion protein expression	18
	3.3.2.1	Large scale expression	18
	3.3.2.2	Buffer exchange	19
	3.3.2.3	Cleavage of SUMO-hBD9 fusion protein	19
	3.3.2.4	Purification of free hBD9 peptide	20
	3.3.2.5	Western blot	20
	3.3.3	Antimicrobial assay	20
	3.3.4	Kinetics of bactericidal efficacy	21
	3.3.5	Effect of salty environment	21
	3.3.6	Effect of high ionicity	22
3.4		Statistical analysis	22
<b>4</b>	<b>RESULTS</b>		<b>23</b>
	4.1	Transformation into competent Mach1™-T1R <i>Escherichia. coli</i>	23
	4.2	Colony selection and plasmid DNA isolation	23
	4.3	Expression of SUMO-hBD9 and His-Tag purification	24
	4.4	Cleavage of SUMO-hBD9 and purification of hBD9 peptide	26
	4.5	Purification of hBD9 peptide	27
	4.6	Validation of free hBD9 protein	28
	4.7	Antimicrobial Assay of recombinant HBD9	29
	4.8	Kinetics of bactericidal assay	37
	4.9	Effect of salt concentration	45
	4.10	Effect of high ionicity	46
<b>5</b>	<b>DISCUSSION</b>		<b>48</b>
<b>6</b>	<b>SUMMARY, CONCLUSION AND RECOMMENDATION</b>		<b>53</b>
	6.1	Summary and conclusion	53
	6.2	Recommendations for future research	53
	<b>REFERENCES</b>		<b>54</b>
	<b>BIODATA OF STUDENT</b>		<b>61</b>

## LIST OF FIGURES

Figure	Page
2.1 Antimicrobial peptides (AMPs)	6
2.2 Structure of defensin HNP-3	8
2.3 The monomeric and dimeric structures of human beta defensin 2 (hBD2)	9
2.4 Cross sectional view of the eye. This diagram showed the anatomy parts of the human eye	11
2.5 Comparison between the Gram-positive and Gram-negative bacterial cell membrane	13
4.1 Transformation of plasmid into competent Mach1™-T1R <i>Escherichia coli</i> . A 50 µl of transformation reaction was spread on prewarmed LB agar plate supplemented with 50 µg/ml kanamycin. All plates were incubated for 16 hours at 37 °C	23
4.2 Nucleotide sequence of the correct open reading frame (ORF) of DEFB-109 with SUMO	24
4.3 Purification of His-tagged SUMO-hBD9 with Immobilized metal affinity chromatography (IMAC). IMAC chromatogram shows the fractions that contained SUMO-hBD9 were started to elute from fraction B10 to C5 as shown by the arrow head	25
4.4 SDS-PAGE analysis. Lane M; molecular weight markers, lane 1; total protein, lane 2; insoluble fraction, lane 3; crude lysate, lane 4; flow through, lanes 5 and 6; unbound protein, lanes 7,8,9,10,11,12,and13; eluted fractions of B10 to C5. SDS-PAGE analysis shows a dominant protein band with molecular weight approximately 25 kDa	25
4.5 SDS-PAGE analysis following SUMO protease digestion at different incubation time. Lane M; molecular weight markers, lane 1; uncleaved sample, lane 2; 1 hour cleave reaction, lane 3; 2 hours cleave reaction, lane 4; 4 hours cleave reaction and lane 5; 6 hours reaction	26
4.6 Second round of immobilised metal affinity column chromatography. Chromatogram indicates that hBD9 which could not bind the column was collected in the void volume (indicated by an arrow) while His-tagged SUMO was eluted with imidazole	27

4.7	SDS-PAGE analysis of free hBD9 peptide after second round of immobilized metal affinity chromatography. Lane M; molecular weight markers, lane 1; uncleaved sample, lane 2; cleaved sample, lane 3, 4, 5, and 6; flow through, lane 7, 8, 9, 10, 11, 12, 13, and 14; are imidazole eluted fractions. Most of the 6x His-tagged SUMO was eluted in lane 10 at 175mM of imidazole	28
4.8	Western blot analysis of hBD9	29
4.9	Colony Forming Unit (CFU) count to determine concentration of $1 \times 10^6$ CFU/ml for <i>Staphylococcus aureus</i> . The number label on each grid indicates the 10-fold serial dilution. The average number of colonies from three plates (triplicate) in the red circles ( $1 \times 10^4$ dilution) was calculated	30
4.10	CFU count to define the concentration of $1 \times 10^6$ CFU/ml for Gram-negative <i>Pseudomonas aeruginosa</i> . The average number of colonies from two plates (duplicate) ( $1 \times 10^4$ dilution) was calculated	31
4.11	MIC of hBD9 against <i>Staphylococcus aureus</i> . All tubes contain $1 \times 10^6$ CFU/mL bacteria. HBD9 at different concentrations was added into the tubes. All tubes were then incubated at $37^\circ \text{C}$ for 4, 8 and 24 hours	32
4.12	MIC of hBD9 against <i>Pseudomonas aeruginosa</i> . All tubes contain $1 \times 10^6$ CFU/mL bacteria. HBD9 at different concentrations was added into the tubes. All tubes were then incubated at $37^\circ \text{C}$ for 4, 8 and 24 hours	33
4.13	Percentages of <i>Staphylococcus aureus</i> inhibited by different concentrations of hBD9. After the first 4 hours of incubation, $37.5 \mu\text{g/mL}$ of hBD9 inhibited the growth of <i>S. aureus</i> . Lower concentrations of hBD9 exhibited the growth of <i>S. aureus</i> proportional to the incubation periods. HBD9 at $150 \mu\text{g/mL}$ has been shown to inhibit ~70% of the <i>S. aureus</i> after 8 hours and almost 99% inhibition after 24 hours of incubation. All bacteria cultures were incubated at $37^\circ \text{C}$	34
4.14	Percentages of <i>Pseudomonas aeruginosa</i> inhibited by different concentrations of hBD9. At the first 4 hours of incubation only $400 \mu\text{g/mL}$ of hBD9 inhibited ~99% of bacteria. After 8 and 24 hours incubation, minimum inhibition concentration (MIC) cannot be determined. Most of the hBD9 concentrations exhibited the growth of <i>Pseudomonas aeruginosa</i>	34
4.15	Minimum bactericidal concentrations (MBC) of hBD9 against <i>Staphylococcus aureus</i> . MBC determination after	35

4.16	Minimum bactericidal concentrations (MBC) of hBD9 against <i>Pseudomonas aeruginosa</i> . MBC determination at	36
4.17	Kinetic killing of <i>Staphylococcus aureus</i> against hBD9. Each 10-fold serial dilution was labelled on the plates	39
4.18	Percentage of <i>Staphylococcus aureus</i> survival against hBD9 by three independent tests (triplicate). The bacteria survival decreased by increasing the incubation time. Most of the bacteria killed after 4 hours of incubation	40
4.19	Average percentages by three independent test of <i>Staphylococcus aureus</i> survival against hBD9. The hBD9 (300 µg/mL) inhibited the growth of <i>Staphylococcus aureus</i> after 2 hour of incubation and most of the bacteria were inhibited after 4 to 24 hours incubation	41
4.20	Kinetic killing of <i>Pseudomonas aeruginosa</i> against hBD9. The grids are labelled with 10-fold serial dilutions	43
4.21	Percentage of <i>Pseudomonas aeruginosa</i> survival against hBD9 by three independent tests (triplicate). The bacteria survival was increased by increasing the incubation time. Most of the bacteria survived after 4 hours incubation	44
4.22	Average percentage by three independent test of <i>Pseudomonas aeruginosa</i> survival against hBD9. The hBD9 (400 µg/mL) exhibited growth of <i>Pseudomonas aeruginosa</i> after 2 hour incubation and most of the bacteria survived after 4 to 8 hours incubation as shown in the graph	45
4.23	The effect of salt concentration on antimicrobial activity of <i>Staphylococcus aureus</i> using 300µg/ml hBD9. The bar chart represents the mean of three tests of each concentration and their standard error. There were no significant different ( $p<0.05$ ), $p= 0.37$ between lower or higher concentration of NaCl against their antimicrobial activity	46
4.24	The effect of high ionicity on antimicrobial activity of <i>Pseudomonas aeruginosa</i> with 300ug/ml hBD9. The bar chart represents the mean of three tests of each concentrations and their standard error. There were no significant different ( $p<0.05$ ), $p=0.65$ between lower or higher concentration of MgCl <sub>2</sub> against their antimicrobial activity	47

## LIST OF ABBREVIATIONS

%	Percent
>	More than
° C	Degree celcius
μl	Microliter
θ	Delta
μM	Micrometer
α	Alpha
β	Beta
AMPs	Antimicrobial peptides
ATP	Adenosine triphosphate
BNBD	Bovine neutrophil β-defensin
Ca <sup>2+</sup>	Calcium
CaCl <sub>2</sub>	Calcium chloride
CFU	Colony forming unit
Co <sup>2+</sup>	Cobalt
Cu <sup>2+</sup>	Copper
DNA	Deoxyribonucleic acid
DEFB109	Human beta defensin 9 gene
DMSO	Dimethyl sulfoxide
DTT	Dithiothreitol
ECL	Chemiluminescence
ECM	Extracellular matrix
et al.,	and others
E1	Ubiquitin-activating <i>enzymes</i>



FPLC	<i>Fast protein liquid chromatography</i>
FPSK	<i>Fakulti perubatan sains kesihatan</i>
GST	<i>Glutathione S-transferase</i>
HA	<i>Hemagglutinin antigen</i>
HBD1	Human beta defensin 1
HBD2	Human beta defensin 2
HBD3	Human beta defensin 3
HBD5	Human beta defensin 5
HBD6	Human beta defensin 6
HBD9	Human beta defensin 9
HCl	Hydrochloric acid
HDP	Host defence peptide
HNP	Human neutrophil peptide
HRP	Horse radish peroxidase
HSV	Herpes Simplex Virus
IL-1	Interlukien-1
IL-1 $\beta$	Interlukien-1 Beta
IPTG	Isopropyl-D-thiogalactoside
KCl	Potassium chloride
kDa	Kilo Dalton
K <sub>2</sub> HPO <sub>4</sub>	Potassium phosphate
LB	Luria bertani
LC	Lethal concentration
M	Molar
MBC	Minimal bactericidal concentration

MBP	Maltose binding protein
MIC	Minimal inhibitory concentration
Mg <sup>2+</sup>	Magnesium
MgCl	Magnesium chloride
mg	Microgram
mL	Millilitre
mM	Milimeter
mRNA	Messenger RNA
NaCl	Sodium chloride
Na <sub>3</sub> PO <sub>4</sub>	Sodium phosphate
Ni <sup>2+</sup>	<i>Nickel</i>
NK	Natural killer cell
NLRs	NOD like receptors
Nus A	Protein Nus A
OD	Optical density
PAMPs	Pathogen associated molecular patterns
pH	Potential hydrogen
PCR	Polymerase chain reaction
PVDF	Polyvinylidene difluoride
RNA	Ribonucleic acid
rpm	Revolutions per minute
SARs-CoV	Severe acute respiratory syndrome coronavirus
SDS PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SOC	Super optimal catabolite repression

SUMO	Small ubiquitin like modifier
TBS	Tris buffered saline
TBS-T	Tris buffered saline with detergent tween 20
TLRs	Toll-like receptors
TNF- $\alpha$	Tumor necrosis factor – alpha
TRX	Thioredoxin
U	Unit
UB	Ubiquitin
UK	United Kingdom
Ulp 1	Ubl-specific protease 1
USA	United State of America

# CHAPTER 1

## INTRODUCTION

### 1.1 Background

The term antimicrobial peptides (AMPs) are descriptive for a family of peptides with antimicrobial properties. Various AMPs have been isolated from many classes of all kingdoms and they are classified based on their structures and amino acid composition (R. Koczulla & Bals, 2007). Besides having broad antimicrobial spectrum activities, AMPs are also involved in cellular processes such as immune induction, wound healing, cell proliferation, cytokine release, protease-antiprotease balance, chemotaxis and angiogenesis (Szyk et al., 2006).

AMPs play an important reaction towards pathogens. They have small endogenous cationic particles that are released by epithelial and phagocytic cells. The antimicrobial events of AMPs are focused towards bacteria, viruses, yeast and fungi. Once AMPs reached their target microbial membrane, they kill the microbial host through various mechanisms (Szyk et al., 2006). AMPs function's supported in innate and adaptive immunity by do their roles as immunomodulatory activity like leukocyte migration and direct inactivation.

Among the AMPs, defensins are the major AMPs developed in ocular surface (McDermott, 2009a). Defensins are the largest family of antimicrobial peptides and also they are the most studied. To date approximately 300 defensins have been identified from a wide range of organisms including mammals, plants, birds, invertebrates, and recently in the ebony-cup fungus. Defensins are a group of peptides that are part of the basic components of the host defense system. They can identify and neutralize microorganisms rapidly and specifically (Dhople, Krukemeyer, & Ramamoorthy, 2006). They are synthesized as preproteins and undergo post translational process before transformed into a biologically active peptide.

Defensins are divided into alpha- and beta-defensins depending on their disulfide bridging pattern. The  $\alpha$ - and  $\beta$ -defensins are able to induce the release of cytokines, histamine and prostaglandin D2 from the mast cells and alter cell migration and maturation. In addition, defensins are classically described as antimicrobial peptides and are also involved in immune modulation, fertility, cell development and wound healing.

Native human  $\alpha$ -defensin peptide also known as human neutrophil peptides (HNP) can be isolated from neutrophils. The first defensin was isolated from the rabbit alveolar macrophages and the first defensin discovered in multicellular organisms is  $\alpha$ -defensins (Selsted, Brown, DeLange, & Lehrer, 1983).

Beta defensins, which belong to the family of mammalian defensins, form part of the defence system rendering the epithelial surfaces resistance to microbial colonization and they also play a role in the innate immune system.  $\beta$ -defensins genes are liable for the production of antimicrobial peptides that are found in the white blood cells such as granulocytes, macrophages, Natural Killer (NK) cells and also in the epithelial cells.

$\alpha$ -defensins was derived from infiltrating neutrophils. McDermott, 2009 reported that ocular surface epithelial cells synthesized and secreted the  $\beta$ -defensins (McDermott, 2009b). Both cornea and conjunctival expressed the  $\beta$ -defensins. Human beta-defensin 1 (hBD1) has been shown effectively expressed while human beta-defensin 2 (hBD2) expression is variable because it is infrequently expressed by normal tissues (Haynes, Tighe, & Dua, 1998). The expression of human beta-defensin 4 (hBD4) in cultured ocular surface of epithelial cells has been detected but in non-cultured samples it is only found irregularly (McIntosh et al., 2005). Human beta-defensin 3 (hBD3) also has been shown to be effective against *Pseudomonas aeruginosa* and *Staphylococcus* strains (Dua, Otri, Hopkinson, & Mohammed, 2014). In addition human beta-defensin 5 (hBD5) and human beta-defensin 6 (hBD6) were found to have antimicrobial activities against *Escherichia coli* but not *Staphylococcus aureus* (Huang, Ching, Jiang, & Leong, 2008).

A study on expression of a novel  $\beta$ -defensin gene, *DEFB 109* has been discovered in the ocular surface epithelia (Abedin, Mohammed, Hopkinson, & Dua, 2008). Human Beta Defensin 9 (hBD9) is a newly discovered defensin and has not been isolated and fully characterised. HBD9 was first reported on the ocular surface by Abedin and co-workers in 2008 (Abedin et al., 2008)(Abedin et al., 2008). Previous study demonstrated that hBD9 mRNA is expressed constitutively but subsequently down regulated in the presence of ocular surface infection and inflammation (Abedin et al., 2008). This is in good agreement with the earlier findings reported by Premratanachai et al (2004) who demonstrated that *in vitro* stimulation of gingival keratinocytes with *Candida albicans* down-regulate the hBD9 mRNA after the stimulation (Premratanachai et al., 2004). Toll-like receptors (TLRs) and Nod-like receptors (NLRs) are two main receptor of innate immune response. These receptor have high affinity for pathogen recognition and cytokine modulation and AMP expression (Akira, Uematsu, & Takeuchi, 2006). A study on hBD9 found it has a unique mechanism. HBD9 expression can be downregulated and upregulated in a time dependent manner in response to the stimulation of different TLRs and NLRs with specific PAMs and IL-1 $\beta$  (Mohammed et al., 2010). Different expression of hBD9 suggest that it may have other roles, like in between innate and adaptive immune system and immunomodulation to the attributed antimicrobial response (Mohammed et al., 2010).

At the protein expression level, hBD9 is constitutively expressed in all region of normal ocular surface tissue and it is primarily localised at the basal epithelial cells of the conjunctiva but more superficially in cornea epithelium (Mohammed et al., 2010). The existing data interestingly points towards possibly different or additional roles it

could play in the host immune system including in the ocular surface against invading pathogens.

Application of fusion technology is notably effective to enhance the solubility and expression level of recombinant proteins. With respect to their advantages, fusion partners are categorized differently. These advantages include improvement of recombinant protein solubility, recombinant protein expression level, reduction in proteolytic degradation of the recombinant protein, and simplify the purification protocol and detection.

Traditionally, hBD9 was expressed using conventional pET fusion system. These conventional protein expression systems produced low level of recombinant hBD9, which was also associated with protein insolubility, non-specific proteolysis, and high enzyme to substrate ratio as well as narrow pH and urea tolerance for protein stability. In addition, the isolation of the target protein following cleavage required multiple chromatographical steps with variable retrieval rates. Overall, this has increased the production cost. In order to improve the protein production yield, solubility and stability, hBD9 gene has been cloned into a pET-SUMO protein expression system. The fusion protein of hBD9 and SUMO was expressed by Isopropyl- $\beta$ -D-thiogalactoside (IPTG) induction and purified with immobilized metal affinity column (IMAC) attached to a Fast Protein Liquid Chromatography (FPLC) system. The SUMO protein and its 6x His-tagged was removed by SUMO protease before the cleaved hBD9 was reversed purified with another round of IMAC chromatography. Purified hBD9 was assayed for its biological activity using antimicrobial assay

## **1.2 Objectives**

### **1.2.1 General objectives**

The general objective was to produce antimicrobial peptide hBD9 and determined its antimicrobial efficacy against *Staphylococcus aureus* and *Pseudomonas aeruginosa* in various salt concentrations.

### **1.2.2 The specific objectives of this study includes:**

- a. To express and purify the hBD9 protein
- b. To determine antimicrobial activity of hBD9 protein against *Staphylococcus aureus* and *Pseudomonas aeruginosa*

## REFERENCES

- Abedin, A., Mohammed, I., Hopkinson, A., & Dua, H. S. (2008). A Novel Antimicrobial Peptide on the Ocular Surface Shows Decreased Expression in Inflammation and Infection. *Investigative Ophthalmology & Visual Science*, 49(1), 28. <http://doi.org/10.1167/iovs.07-0645>
- Akira, S., Uematsu, S., & Takeuchi, O. (2006). Pathogen recognition and innate immunity. *Cell*. <http://doi.org/10.1016/j.cell.2006.02.015>
- Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. *Journal of Antimicrobial Chemotherapy*, 48(suppl 1), 5–16. [http://doi.org/10.1093/jac/48.suppl\\_1.5](http://doi.org/10.1093/jac/48.suppl_1.5)
- Befus, A. D., Mowat, C., Gilchrist, M., Hu, J., Solomon, S., & Bateman, A. (1999). Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. *Journal of Immunology (Baltimore, Md. : 1950)*, 163, 947–953. [http://doi.org/ji\\_v163n2p947](http://doi.org/ji_v163n2p947) [pii]
- Bensch, K. W., Raida, M., Mägert, H.-J., Schulz-Knappe, P., & Forssmann, W.-G. (1995). hBD-1: a novel  $\beta$ -defensin from human plasma. *FEBS Letters*, 368, 331–335. [http://doi.org/10.1016/0014-5793\(95\)00687-5](http://doi.org/10.1016/0014-5793(95)00687-5)
- Bharathi, Mj., Amuthan, M., Viswanathan, S., Ramesh, S., & Ramakrishnan, R. (2010). Prevalence of bacterial pathogens causing ocular infections in South India. *Indian Journal of Pathology and Microbiology*, 53(2), 281. <http://doi.org/10.4103/0377-4929.64336>
- Boman, H. G. (2000). Innate immunity and the normal microflora. *Immunological Reviews*, 173(1), 5–16. <http://doi.org/10.1034/j.1600-065X.2000.917301.x>
- Brogden, K. A. (2005). Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nature Reviews Microbiology*, 3(3), 238–250. <http://doi.org/10.1038/nrmicro1098>
- Brown, K. L., & Hancock, R. E. W. (2006). Cationic host defense (antimicrobial) peptides. *Current Opinion in Immunology*. <http://doi.org/10.1016/j.coi.2005.11.004>
- Delcour, A. H. (2009). Outer membrane permeability and antibiotic resistance. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics*, 1794(5), 808–816. <http://doi.org/10.1016/j.bbapap.2008.11.005>
- Dhople, V., Krukemeyer, A., & Ramamoorthy, A. (2006). The human beta-defensin-3, an antibacterial peptide with multiple biological functions. *Biochimica et Biophysica Acta - Biomembranes*. <http://doi.org/10.1016/j.bbamem.2006.07.007>

- Dua, H. S., Otri, A. M., Hopkinson, A., & Mohammed, I. (2014). In vitro studies on the antimicrobial peptide human beta-defensin 9 (HBD9): signalling pathways and pathogen-related response (an American Ophthalmological Society thesis). *Transactions of the American Ophthalmological Society*, 112, 50–73.
- Ganz, T. (2003). The Role of Antimicrobial Peptides in Innate Immunity. *Integrative and Comparative Biology*, 43(2), 300–304. <http://doi.org/10.1093/icb/43.2.300>
- Ganz, T., & Lehrer, R. I. (1995). Defensins. *Pharmacology & Therapeutics*, 66(2), 191–205. [http://doi.org/10.1016/0163-7258\(94\)00076-F](http://doi.org/10.1016/0163-7258(94)00076-F)
- Ganz, T., Selsted, M. E., Szklarek, D., Harwig, S. S., Daher, K., Bainton, D. F., & Lehrer, R. I. (1985). Defensins. Natural peptide antibiotics of human neutrophils. *Journal of Clinical Investigation*, 76(4), 1427–1435. <http://doi.org/10.1172/JCI112120>
- Groenink, J., Walgreen-Weterings, E., Van 'T Hof, W., Veerman, E. C. I., & Nieuw Amerongen, A. V. (1999). Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. *FEMS Microbiology Letters*, 179(2), 217–222. [http://doi.org/10.1016/S0378-1097\(99\)00414-0](http://doi.org/10.1016/S0378-1097(99)00414-0)
- Hancock, R. E. W., & Diamond, G. (2000). The role of cationic antimicrobial peptides in innate host defences. *Trends in Microbiology*. [http://doi.org/10.1016/S0966-842X\(00\)01823-0](http://doi.org/10.1016/S0966-842X(00)01823-0)
- Hancock, R. E. W., & Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nature Biotechnology*. <http://doi.org/10.1038/nbt1267>
- Harder, J., Bartels, J., Christophers, E., & Schröder, J.-M. (1997). A peptide antibiotic from human skin. *Nature*, 387(6636), 861–861. <http://doi.org/10.1038/43088>
- Harder, J., Siebert, R., Zhang, Y., Matthiesen, P., Christophers, E., Schlegelberger, B., & Schröder, J. M. (1997). Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. *Genomics*, 46(3), 472–5. <http://doi.org/10.1006/geno.1997.5074>
- Haynes, R. J., Tighe, P. J., & Dua, H. S. (1998). Innate defence of the eye by antimicrobial defensin peptides. *Lancet*, 352(9126), 451–452. [http://doi.org/10.1016/S0140-6736\(05\)79185-6](http://doi.org/10.1016/S0140-6736(05)79185-6)
- Haynes, R. J., Tighe, P. J., & Dua, H. S. (1999). Antimicrobial defensin peptides of the human ocular surface. *British Journal of Ophthalmology*, 83(6), 737–741. <http://doi.org/10.1136/bjo.83.6.737>



- Hiratsuka, T., Nakazato, M., Date, Y., Ashitani, J., Minematsu, T., Chino, N., & Matsukura, S. (1998). Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. *Biochemical and Biophysical Research Communications*, 249(3), 943–947.
- Hochstrasser, M. (2010). NIH Public Access, 458(7237), 1–19. <http://doi.org/10.1038/nature07958>.Origin
- Hoover, D. M., Chertov, O., & Lubkowski, J. (2001). The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. *The Journal of Biological Chemistry*, 276(42), 39021–6. <http://doi.org/10.1074/jbc.M103830200>
- Huang, L., Ching, C. B., Jiang, R., & Leong, S. S. J. (2008). Production of bioactive human beta-defensin 5 and 6 in *Escherichia coli* by soluble fusion expression. *Protein Expression and Purification*, 61(2), 168–174. <http://doi.org/10.1016/j.pep.2008.05.016>
- Izadpanah, A., & Gallo, R. L. (2005). Antimicrobial peptides. *Journal of the American Academy of Dermatology*, 52(3), 381–390. <http://doi.org/10.1016/j.jaad.2004.08.026>
- Jentsch, S., & Pyrowolakis, G. (2000). Ubiquitin and its kin: How close are the family ties? *Trends in Cell Biology*, 10(8), 335–342. [http://doi.org/10.1016/S0962-8924\(00\)01785-2](http://doi.org/10.1016/S0962-8924(00)01785-2)
- Johnson, E. S., Schwienhorst, I., Dohmen, R. J., Blobel, G., & Ju, R. (1997). The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. *Embo Journal*, 16(18), 5509–5519. <http://doi.org/10.1093/emboj/16.18.5509>
- Kaushal, A., Gupta, K., & Van Hoek, M. L. (2016). Characterization of *Cimex lectularius* (bedbug) defensin peptide and its antimicrobial activity against human skin microflora. *Biochemical and Biophysical Research Communications*, 470(4), 955–960. <http://doi.org/10.1016/j.bbrc.2016.01.100>
- Keymanesh, K., Soltani, S., & Sardari, S. (2009). Application of antimicrobial peptides in agriculture and food industry. *World Journal of Microbiology and Biotechnology*. <http://doi.org/10.1007/s11274-009-9984-7>
- Kimple, M. E., Brill, A. L., & Pasker, R. L. (2013). Overview of affinity tags for protein purification. *Current Protocols in Protein Science*, (SUPPL.73). <http://doi.org/10.1002/0471140864.ps0909s73>
- Koczulla, A. R., & Bals, R. (2003). Antimicrobial peptides: Current status and therapeutic potential. *Drugs*. <http://doi.org/10.2165/00003495-200363040-00005>

- Koczulla, R., & Bals, R. (2007). CHAPTER 10 MODULATE ANGIOGENESIS Abstract :, 49(0), 191–196.
- Kunt, H. (2016). Investigating Science Student Teachers ' Ideas about Function and Anatomical Form of Two Human Sensory Organs , the Eye and the Ear. *International Journal of Environmental & Science Education*, 11(5), 535–542. <http://doi.org/10.12973/ijese.2016.406a>
- Lan, W., Petznick, A., Heryati, S., Rifada, M., & Tong, L. (2012). Nuclear factor- $\kappa$ B: Central regulator in ocular surface inflammation and diseases. *Ocular Surface*, 10(3), 137–148. <http://doi.org/10.1016/j.jtos.2012.04.001>
- Lehrer, R. I., Daher, K., Ganz, T., & Selsted, M. E. (1985). Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. *Journal of Virology*, 54(2), 467–72. Retrieved from <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=254818&tool=pmcentrez&rendertype=abstract>
- Liu, A. Y., Destoumieux, D., Wong, A. V., Park, C. H., Valore, E. V., Liu, L., & Ganz, T. (2002). Human  $\alpha$ -defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. *Journal of Investigative Dermatology*, 118(2), 275–281. <http://doi.org/10.1046/j.0022-202x.2001.01651.x>
- Malakhov, M. P., Mattern, M. R., Malakhova, O. A., Drinker, M., Weeks, S. D., & Butt, T. R. (2004). SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. *Journal of Structural and Functional Genomics*, 5(1–2), 75–86. <http://doi.org/10.1023/B:JSFG.0000029237.70316.52>
- Marblestone, J. G. (2006). Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO. *Protein Science*, 15(1), 182–189. <http://doi.org/10.1110/ps.051812706>
- Marblestone, J. G., Edavettal, S. C., Lim, Y., Lim, P., Zuo, X. U. N., & Butt, T. R. (2006). Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO, 182–189. <http://doi.org/10.1110/ps.051812706.for>
- Marx, W. (2012). Tracking historical papers and their citations. *European Science Editing*, 38(2), 35–37. <http://doi.org/10.1023/B>
- McDermott, A. M. (2004). Defensins and other antimicrobial peptides at the ocular surface. *Ocular Surface*. [http://doi.org/10.1016/S1542-0124\(12\)70111-8](http://doi.org/10.1016/S1542-0124(12)70111-8)
- McDermott, A. M. (2009a). The role of antimicrobial peptides at the ocular surface. *Ophthalmic Research*, 41(2), 60–75. <http://doi.org/10.1159/000187622>

- McDermott, A. M. (2009b). The role of antimicrobial peptides at the ocular surface. *Ophthalmic Research*. <http://doi.org/10.1159/000187622>
- McIntosh, R. S., Cade, J. E., Al-Abed, M., Shanmuganathan, V., Gupta, R., Bhan, A., ... Dua, H. S. (2005). The spectrum of antimicrobial peptide expression at the ocular surface. *Investigative Ophthalmology & Visual Science*, 46(4), 1379–1385. <http://doi.org/10.1167/iovs.04-0607>
- Melchior, F. (2000). SUMO--nonclassical ubiquitin. *Annual Review of Cell and Developmental Biology*, 16, 591–626. <http://doi.org/10.1146/annurev.cellbio.16.1.591>
- Miller, J. H. (1972). Experiments in molecular genetics. *Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY*, 433, 352–355. <http://doi.org/papers2://publication/uuid/28F839D6-A272-4D50-9114-D2769DE72B38>
- Mohammed, I., Suleman, H., Otri, A. M., Kulkarni, B. B., Chen, P., Hopkinson, A., & Dua, H. S. (2010). Localization and gene expression of human beta-defensin 9 at the human ocular surface epithelium. *Investigative Ophthalmology & Visual Science*, 51(9), 4677–4682. <http://doi.org/10.1167/iovs.10-5334>
- Mossessova, E., & Lima, C. D. (2000). Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. *Molecular Cell*, 5(5), 865–876. [http://doi.org/10.1016/S1097-2765\(00\)80326-3](http://doi.org/10.1016/S1097-2765(00)80326-3)
- Müller, S., Hoegge, C., Pyrowolakis, G., & Jentsch, S. (2001). Sumo, ubiquitin's mysterious cousin. *Nature Reviews Molecular Cell Biology*. <http://doi.org/10.1038/35056591>
- Mygind, P. H., Fischer, R. L., Schnorr, K. M., Hansen, M. T., Sönksen, C. P., Ludvigsen, S., ... Kristensen, H.-H. (2005). Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. *Nature*, 437(7061), 975–980. <http://doi.org/10.1038/nature04051>
- Panja, S., Saha, S., Jana, B., & Basu, T. (2006). Role of membrane potential on artificial transformation of *E. coli* with plasmid DNA. *Journal of Biotechnology*, 127(1), 14–20. <http://doi.org/10.1016/j.jbiotec.2006.06.008>
- Patil, A. A., Cai, Y., Sang, Y., Blecha, F., & Zhang, G. (2005). Cross-species analysis of the mammalian beta-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract. *Physiological Genomics*, 23(1), 5–17. <http://doi.org/10.1152/physiolgenomics.00104.2005>
- Premratanachai, P., Joly, S., Johnson, G. K., McCray, P. B., Jia, H. P., & Guthmiller, J. M. (2004). Expression and regulation of novel human  $\beta$ - defensins in gingival keratinocytes. *Oral Microbiology and Immunology*, 19(2), 111–117.

- Raj, P. A., & Dentino, A. R. (2002). Current status of defensins and their role in innate and adaptive immunity. *Science*, *206*, 9–18.
- Riedl, S., Zweytick, D., & Lohner, K. (2011). Membrane-active host defense peptides - Challenges and perspectives for the development of novel anticancer drugs. *Chemistry and Physics of Lipids*, *164*(8), 766–781. <http://doi.org/10.1016/j.chemphyslip.2011.09.004>
- Schibli, D. J., Hunter, H. N., Aseyev, V., Starner, T. D., Wiencek, J. M., McCray, P. B., ... Vogel, H. J. (2002). The Solution Structures of the Human  $\beta$ -Defensins Lead to a Better Understanding of the Potent Bactericidal Activity of HBD3 against *Staphylococcus aureus* \*. *Journal of Biological Chemistry*, *277*(10), 8279–8289. <http://doi.org/10.1074/jbc.M108830200>
- Schibli, D. J., Hunter, H. N., Aseyev, V., Starner, T. D., Wiencek, J. M., McCray, P. B., ... Vogel, H. J. (2002). The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against *Staphylococcus aureus*. *The Journal of Biological Chemistry*, *277*(10), 8279–89. <http://doi.org/10.1074/jbc.M108830200>
- Selsted, M. E., Brown, D. M., DeLange, R. J., & Lehrer, R. I. (1983). Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages. *Journal of Biological Chemistry*, *258*(23), 14485–14489.
- Selsted, M. E., Tang, Y. Q., Morris, W. L., McGuire, P. A., Novotny, M. J., Smith, W., ... Cullor, J. S. (1996). Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. *The Journal of Biological Chemistry*. [http://doi.org/10.1016/S0167-7799\(00\)88947-7](http://doi.org/10.1016/S0167-7799(00)88947-7)
- Sternsdorf, T., Jensen, K., & Freemont, P. S. (2003). Sumo. *Current Biology*, *13*(7), R258–R259. [http://doi.org/10.1016/S0960-9822\(03\)00193-3](http://doi.org/10.1016/S0960-9822(03)00193-3)
- Suresh, A., & Verma, C. (2006). Modelling study of dimerization in mammalian defensins. *BMC Bioinformatics*, *7*(SUPPL.5). <http://doi.org/10.1186/1471-2105-7-S5-S17>
- Szyk, A., Wu, Z., Tucker, K., Yang, D. E., Lu, W., & Lubkowski, J. (2006). and HD6, (Zasloff 2002), 2749–2760. <http://doi.org/10.1110/ps.062336606>.
- Tang, Y. Q., Yuan, J., Osapay, G., Osapay, K., Tran, D., Miller, C. J., ... Selsted, M. E. (1999). A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. *Science (New York, N.Y.)*, *286*(5439), 498–502. <http://doi.org/10.1126/science.286.5439.498>
- Valore, E. V, Park, C. H., Quayle, a J., Wiles, K. R., McCray, P. B., & Ganz, T. (1998). Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. *The Journal of Clinical Investigation*, *101*(8), 1633–1642. <http://doi.org/10.1172/JCI1861>

- Veldhuizen, E. J. A., Rijnders, M., Claassen, E. A., van Dijk, A., & Haagsman, H. P. (2008). Porcine  $\beta$ -defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. *Molecular Immunology*, 45(2), 386–394. <http://doi.org/10.1016/j.molimm.2007.06.001>
- Wang, Z., Li, H., Guan, W., Ling, H., Wang, Z., Mu, T., ... Fang, X. (2010). Human SUMO fusion systems enhance protein expression and solubility. *Protein Expression and Purification*, 73(2), 203–208. <http://doi.org/10.1016/j.pep.2010.05.001>
- Weber, K., Pringle, J. R., & Osborn, M. (1972). Measurement of Molecular Weights by Electrophoresis on SDS-Acrylamide Gel. *Methods in Enzymology*, 26(C), 3–27. [http://doi.org/10.1016/S0076-6879\(72\)26003-7](http://doi.org/10.1016/S0076-6879(72)26003-7)
- Willoughby, C. E., Ponzin, D., Ferrari, S., Lobo, A., Landau, K., & Omidi, Y. (2010). Review Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function – a review, (May), 2–11. <http://doi.org/10.1111/j.1442-9071.2010.02363.x>
- Xu, Z., Zhong, Z., Huang, L., Peng, L., Wang, F., & Cen, P. (2006). High-level production of bioactive human beta-defensin-4 in Escherichia coli by soluble fusion expression. *Applied Microbiology and Biotechnology*, 72(3), 471–479. <http://doi.org/10.1016/j.reactfunctpolym.2005.10.008>
- Zanetti, M., Gennaro, R., & Romeo, D. (1995). Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. *FEBS Letters*. [http://doi.org/10.1016/0014-5793\(95\)01050-O](http://doi.org/10.1016/0014-5793(95)01050-O)
- Zasloff, M. (2002). Antimicrobial peptides of multicellular organisms. *Nature*, 415(0028–0836 (Print)), 389–395. <http://doi.org/10.1038/415389a>
- Zelezetsky, I., & Tossi, A. (2006). Alpha-helical antimicrobial peptides-Using a sequence template to guide structure-activity relationship studies. *Biochimica et Biophysica Acta - Biomembranes*. <http://doi.org/10.1016/j.bbamem.2006.03.021>
- Zhao, L., & Lu, W. (2014). Defensins in innate immunity. *Current Opinion in Hematology*, 21(1), 37–42. <http://doi.org/10.1097/MOH.0000000000000005>
- Zimmerman, G. R., Legault, P., Selsted, M. E., & Pardi, A. (1995). Solution structure of bovine  $\alpha$ -defensin-12: the peptide fold of the  $\alpha$ -defensins is identical to that of the classical defensins. *Biochemistry*, 34, 13663–13671.
- Zuo, X., Li, S., Hall, J., Mattern, M. R., Tran, H., Shoo, J., ... Butt, T. R. (2005). Enhanced expression and purification of membrane proteins by SUMO fusion in escherichia coli. *Journal of Structural and Functional Genomics*, 6(2–3), 103–111. <http://doi.org/10.1007/s10969-005-2664-4>